Search results
Showing 16 to 30 of 66 results for parkinson
Recommendation ID NG71/1 Question Combination treatment for Parkinson's disease dementia:- What is the effectiveness of combination...
MRI-guided focused ultrasound subthalamotomy for treating Parkinson's
In development [GID-IPG10402] Expected publication date: 18 December 2024
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
Physiotherapy:- Does physiotherapy started early in the course of Parkinson's disease, as opposed to after motor symptom onset, confer...
Question Orthostatic hypotension treatment:- For people with Parkinson's disease, what is the most effective pharmacological treatment...
MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease, which could include randomised...
for rapid eye movement sleep behaviour disorder (RBD) in people with Parkinson's disease? Any explanatory notes(if applicable) Why this...
A quick and easy-to-read guide for care home managers about achieving good oral health in care homes.
Extradural motor cortex stimulation (EMCS) for Parkinson's disease
Register an interest in this interventional procedure ...
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Awaiting development [GID-TA10773] Expected publication date: TBC
This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186
This quality standard covers the prevention, diagnosis and management of delirium in adults (aged 18 and over) in hospital or long-term care settings (such as residential care or nursing homes). It describes high-quality care in priority areas for improvement.
View quality statements for QS63Show all sections
Sections for QS63
- Quality statements
- Quality statement 1: Assessing recent changes that may indicate delirium
- Quality statement 2: Interventions to prevent delirium
- Quality statement 3: Use of antipsychotic medication for people who are distressed
- Quality statement 4: Information and support
- Quality statement 5: Communication of diagnosis to GPs
- Update information
- About this quality standard
(2020) to estimate quality-adjusted life years (QALYs) from the Unified Parkinson's Disease Rating Scale (UPDRS) domain scores. The...
Delirium: prevention, diagnosis and management in hospital and long-term care (CG103)
This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications.
Urinary incontinence in neurological disease: assessment and management (CG148)
This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.